AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29305240
Drug: RUSF+Arg/Citr (Arg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUSF+Arg/Citr (Arg, 0.2 g/kg/day; Citr, 0.1 g/kg/day) with daily chloroquine (50 mg)
Trial: 17493066
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with latex extract
Trial: 17239657
Drug: sumanirole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumanirole (all doses)
Trial: 14971965
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g Cr + 18 g dextrose taken 4 times per day for 5 days
Trial: 9389813
Drug: Cyproterone acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate, 12.5 mg, and T undecanoate, 80 mg, administered orally twice daily for 16 weeks
Trial: 7697688
Drug: Enteric-coated (EC)
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated (EC) naproxen tablets 500 mg twice daily
Trial: 2959197
Drug: Teicoplanin-rifampin combination
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin-rifampin combination
Trial: 27302208
Drug: Monthly vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly vitamin D3 supplementation (40,000 IU/month)
Trial: 17475412
Drug: Antiandrogenic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiandrogenic oral contraceptive (30 microg ethinyl estradiol combined with 3 mg drospirenone) for 3 months
Trial: 15675932
Drug: Caudal S(+)‐ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal S(+)‐ketamine 1 mg.kg(‐1) (group K)
Trial: 15675932
Drug: Caudal S(+)‐ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal S(+)‐ketamine 0.5 mg.kg(‐1) plus neostigmine 10 microg.kg(‐1) (group KN)
Trial: 10030482
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy services
Trial: 7757308
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg t.i.d.)
Trial: 6153847
Drug: L-lysine monohydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine monohydrochloride 1000 mg daily
Trial: 28947022
Drug: FF/UMEC 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC 125 mcg
Trial: 25452139
Drug: FF/UMEC 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC 250 mcg
Trial: 16669728
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 or 30 mg/day)
Trial: 14733999
Drug: PSA between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA between 1.0 and 2.99 ng/ml with f/t PSA ratio < or =20%; 249 biopsies indicated, 159 performed (acceptance 63.9%)
Trial: 9642018
Drug: Semantically complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantically complex verbs (e.g., run)
Trial: 9642018
Drug: Semantically simpler
RxNorm normalized name: Simplera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantically simpler verbs (e.g., go)
Trial: 2379442
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g of glucose daily with no phosphorus
Trial: 2379442
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g of glucose with 7.5 mmol of phosphate daily
Trial: 2379442
Drug: 500 g
RxNorm normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g of glucose with 15 mmol of phosphate daily
Trial: 373776
Drug: Euphyllin retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 700 mg/d
Trial: 373776
Drug: Euphyllin retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 350 mg/d
Trial: 29566588
Drug: ReSET (Strategic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReSET (Strategic Executive Treatment)
Trial: 31157708
Drug: Topical analgesic
RxNorm normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesic gel
Trial: 28494914
Drug: 1mg oral
RxNorm normalized name: AXITINIB 1MG ORAL TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg oral melatonin daily 1 hour before bedtime one day before surgery and for another 5 consecutive days postoperatively
Trial: 26249300
Drug: Telemedicine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine (8 sessions of behavioral activation therapy)
Trial: 26249300
Drug: Same-room treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-room treatment (8 sessions of behavioral activation therapy)
Trial: 22540770
Drug: Ciclosporin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (4 mg/kg/day)
Trial: 22540770
Drug: Prednisolone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.75 mg/kg/day)
Trial: 21079147
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus oral S-1 (40 mg/m2 twice per day) on days 1 to 14
Trial: 19738339
Drug: Artemether-Lumefantrine (Coartem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine (Coartem 20 mg/120 mg)
Trial: 10381993
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nalmefene
Trial: 2828818
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg naloxone
Trial: 7026254
Drug: Ciramadol 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol 20 mg
Trial: 7026254
Drug: Ciramadol 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol 60 mg
Trial: 25157543
Drug: Tailored dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored dietary supplements for twice-daily consumption
Trial: 22121190
Drug: Lopinavir/ritonavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (400 mg twice daily)
Trial: 17418297
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of autologous endothelial progenitor cells (EPCs) plus conventional therapy
Trial: 8737145
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of trovafloxacin
Trial: 1524757
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 10 mg nifedipine after awakening
Trial: 2862057
Drug: Propranolol 120
RxNorm normalized name: propranolol 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 120 mg b.d. for one week
Trial: 31751607
Drug: Blue light
RxNorm normalized name: Ocuvite Blue Light Mini Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue light exposure (30-min pulses daily for 6 weeks, peak λ = 469 nm)
Trial: 31751607
Drug: Amber placebo
RxNorm normalized name: amber
DrugBank: Amber (DB14326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amber placebo light (30-min pulses daily for 6 weeks, peak λ = 578 nm)
Trial: 19515553
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m(2) IV q 4 weeks
Trial: 19515553
Drug: Topotecan (TOPO)
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan (TOPO) 1.5 mg/m(2) IV d1-5 q 3 weeks
Trial: 11555521
Drug: Adenosine pretreatment
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine pretreatment (7‐min infusion of adenosine, total 650 microg/kg)
Trial: 9777976
Drug: becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: becaplermin gel
Trial: 31665507
Drug: Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise and education plus cervico‐mandibular manual therapy
Trial: 16847681
Drug: Triazolam 0.1
RxNorm normalized name: triazolam 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.1 mg/70 kg
Trial: 16847681
Drug: Triazolam 0.2
RxNorm normalized name: triazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.2 mg/70 kg
Trial: 8853263
Drug: Bismuth triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth triple therapy
Trial: 8853263
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor triple therapy
Trial: 28858387
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day plus atorvastatin 40 mg/day
Trial: 27294589
Drug: Travoprost administered
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost administered once daily to both eyes
Trial: 27294589
Drug: Bromfenac sodium
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac sodium hydrate administered twice daily to one eye
Trial: 27294589
Drug: Flavin adenine
RxNorm normalized name: Flavin adenine dinucleotide
DrugBank: Flavin adenine dinucleotide (DB03147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavin adenine dinucleotide sodium administered twice daily to the other eye
Trial: 25240971
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg zinc/day for 8 weeks)
Trial: 20925938
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg vildagliptin once daily
Trial: 18567436
Drug: Artequick (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artequick (3.2 mg/Kg/day of artemisinin, 16 mg/Kg/day of piperaquine, and 0.16 mg/Kg/day of primaquine)
Trial: 18567436
Drug: artesunate-mefloquine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artesunate-mefloquine (4 mg/Kg/day of artesunate, 8 mg/Kg/day of mefloquine)
Trial: 15838471
Drug: Patch angioplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch angioplasty with polyester urethane (Vascular‐patch, B. Braun Medical AG)
Trial: 2126739
Drug: High-dose Estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Estramustine phosphate orally
Trial: 26808136
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin
Trial: 19489707
Drug: Individualized acupuncture
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized acupuncture points according to Traditional Chinese Medicine
Trial: 16861717
Drug: Medical and
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical and surgical coronary disease treatments
Trial: 16861717
Drug: Increased treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased treatment levels to reach 80% of eligible patients
Trial: 2845564
Drug: Diethylcarbamazine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (30 mg/kg/d) for one week
Trial: 573564
Drug: Domperidone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (5 or 10 mg)
Trial: 28719527
Drug: Pupillometry-guided remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pupillometry-guided remifentanil administration
Trial: 23062232
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus oxaliplatin (CapeOX) - capecitabine 1000 mg/m(2) twice daily on days 1-14 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks for up to 9 cycles.
Trial: 19548076
Drug: L-propionyl-carnitine (LPC)
RxNorm normalized name: glycine propionyl-L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionyl-carnitine (LPC) 1.2 g/day + PGE-1 60 mg/day
Trial: 17447874
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (physical activity first, then fat intake 3 months later)
Trial: 17447874
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (fat intake first, then physical activity 3 months later)
Trial: 12699520
Drug: 10 micro
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micro g of sufentanil + 500 micro g of adenosine
Trial: 12699520
Drug: 10 micro
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micro g of sufentanil
Trial: 10895027
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate (5 mg), repeated if necessary
Trial: 10895027
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate
Trial: 8826608
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral etoposide alone for 21 days (arm A)
Trial: 8826608
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral etoposide for 21 days with GM‐CSF, 250 micrograms/m2, s.c. twice daily for the first 10 days of etoposide administration (arm B)
Trial: 8826608
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral etoposide for 21 days with GM‐CSF twice daily for the sixth through second days preceding etoposide administration (arm C)
Trial: 1360464
Drug: Cilest (ethinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilest (ethinyl estradiol 35 micrograms and norgestimate 250 mg) for 21 days, followed by 1-4 days of missed pills depending on the group.
Trial: 1360464
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no missed pills)
Trial: 26053726
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (for patients with negative scans)
Trial: 23580456
Drug: 70 ml
RxNorm normalized name: ALCOHOL 70 mL TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 ml nitrate‐rich concentrated beetroot juice (BR)
Trial: 21135862
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (Ph)
Trial: 21135862
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment (Os)
Trial: 17373905
Drug: PANVAC™ cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PANVAC™ cancer vaccine therapy delivered through recombinant vaccinia and recombinant fowlpox vectors, injected subcutaneously.
Trial: 17373905
Drug: PANVAC™ in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PANVAC™ in combination with conventional chemotherapy and/or radiation.
Trial: 1598096
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin
Trial: 12160204
Drug: Oral tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tobramycin and metronidazole for three days prior to surgery
Trial: 12160204
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic cefmetazole every 3 hours during surgery
Trial: 12160204
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic cefmetazole every 3 hours during surgery and luminal preparation of tobramycin during surgery
Trial: 31574170
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L polyethylene glycol plus ascorbic acid
Trial: 31421096
Drug: Bilateral Hybrid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral Hybrid Therapy (BHT)
Trial: 31421096
Drug: Robot-assisted Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted Therapy (RT)
Trial: 31421096
Drug: Unilateral Hybrid
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral Hybrid Therapy (UHT)
Trial: 26133561
Drug: TAC spray
RxNorm normalized name: triamcinolone Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC spray with no rubbing
Trial: 26133561
Drug: TAC spray
RxNorm normalized name: triamcinolone Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC spray with rubbing
Trial: 20166436
Drug: Promethazine hydrochloride
RxNorm normalized name: Promethazine Hydrochloride
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promethazine hydrochloride determination method using LC-MS in human plasma (0.5 ml)
Trial: 20166436
Drug: Promethazine hydrochloride
RxNorm normalized name: Promethazine Hydrochloride
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promethazine hydrochloride determination method using LC-MS in human urine (0.1 ml)
Trial: 16723363
Drug: Syndromic STI
RxNorm normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syndromic STI packages (containing antibiotics, condoms, partner notification cards, and written information)
Trial: 11416871
Drug: Inhaled Nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide (INO) weaning from 40 ppm
Trial: 11416871
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of INO
Trial: 11416871
Drug: INO weaning
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INO weaning with surfactant therapy
Trial: 11416871
Drug: INO weaning
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INO weaning with specific dose reduction
Trial: 29957756
Drug: Continue metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue metformin during peri-angiography (M (+) group)
Trial: 29957756
Drug: Stop metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop metformin 24 hours prior to procedure (M (−) group)
Trial: 26202461
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavioural therapy (TF-CBT)
Trial: 16863724
Drug: Buckwheat honey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buckwheat honey (50 g carbohydrate)
Trial: 16863724
Drug: Cotton honey
RxNorm normalized name: Cotton
DrugBank: Cotton (DB10707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton honey (50 g carbohydrate)
Trial: 31714309
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative intravenous co‐amoxiclav
Trial: 21738025
Drug: Zonisamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (50 mg/d, titrated up to 200 mg/d)
Trial: 21738025
Drug: Topiramate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (25 mg/d, titrated up to 100 mg/d)
Trial: 19824837
Drug: Respeto/Proteger: Respecting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respeto/Proteger: Respecting and Protecting Our Relationships program; details on dosage and duration not available.
Trial: 16395251
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (VC) infusion, n=20
Trial: 30538796
Drug: Ropivacaine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (200 mg intraoperative, 100 mg postoperative every 8 hours for 2 days)
Trial: 24710974
Drug: OT plus
RxNorm normalized name: Picot Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OT plus EMG‐biofeedback therapy
Trial: 24710974
Drug: OT plus
RxNorm normalized name: Picot Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OT plus neurofeedback therapy
Trial: 18096137
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (300 mg/day) + Transdermal Nicotine Patch (21 mg/24h)
Trial: 18096137
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Transdermal Nicotine Patch (21 mg/24h)
Trial: 16155368
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg subcutaneously twice weekly for 4 weeks)